Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Stock Analysis

Why AXP Energy (ASX:AXP) Is Running an Entitlement Offer as It Refocuses on Oklahoma Oil and Gas-to-Power

The company's flagship is the Charlie #1 well on its 100%-owned EdwardsLeasein Noble County, Oklahoma. AXP said on 23 April 2026 that a pump upgrade delivered 45 barrels of oil equivalent per day (a company claim). In its June 2026Quarterly Reportthe company reported first …

Sonal Goyal | 19 October 2026

Why Australia United Mining (ASX:AYM) Relies on Director-Linked Loans to Hold Its Gold Joint Ventures

According to its quarterly activities report dated 28 July 2026, AYM has two gold projects with historical production, one in New South Wales and one in Queensland. The report describes no established resource.

Sonal Goyal | 19 October 2026

Why Bridge SaaS (ASX:BGE) Is Refocusing on NDIS Software and Disability Services After Selling Its Brightside Stake

Bridge said the sale followed a strategic review. The annual report, published on 30 September 2026, records the sale as effective on 30 June 2026 for $1,500,000 gross. After an $80,000 legal-fee holdback, net proceeds of $1,420,000 were received on 10 July. The company …

Sonal Goyal | 19 October 2026

Why Blaze Minerals (ASX:BLZ) copper exploration in Botswana is tied to a pending acquisition and capital raising

Blaze describes itself as a mineral exploration company looking for high-grade deposits. It holds an agreement to acquire up to a 90 per cent interest in a package of exploration licences in Botswana and Uganda. The Botswana projects are Dinokwe, Kalahari (copper-silver) and Molopo …

Sonal Goyal | 19 October 2026

Why BauMart Holdings (ASX:BMH) Is Testing Modular Housing Alongside Its Supply-Chain and Distribution Business

BauMart listed on the ASX in 2015, having started in building-materials distribution and glass-processing equipment. According to its 29 July 2026 quarterly report, it now describes four areas: international human resources solutions, industrial and construction product distribution including the Washpod product, sustainable energy and …

Sonal Goyal | 19 October 2026

Why Butn (ASX:BTN) is pairing SME receivables funding with a retail credit fund after its FY26 result

Butn describes itself as an Australian funder that eases SME working-capital constraints by financing transactions on the credit of the end debtor, and says it has funded more than A$2.5 billion to Australian businesses.

Sonal Goyal | 19 October 2026

Why Cosmo Metals (ASX:CMO) is funding maiden copper drilling at Mona in northern New South Wales

Cosmo is an early-stage explorer. Its portfolio comprises the Bingara and Nundle projects in northern New South Wales, covering about 743 square kilometres, and the Kanowna gold project near Kalgoorlie in Western Australia. ExplorationAssetswere carried at about A$10.25 million after a A$2.93 millionImpairmentin FY2026.

Sonal Goyal | 19 October 2026

Why Coppermoly (ASX:COY) Has Opened a Strategic Review Across Its Queensland and Western Australian Critical Minerals Tenements

Coppermoly explores for copper, gold and molybdenum in the Mount Isa region of Queensland and, since March 2026, for critical minerals in Western Australia. It has no operating revenue, and its project area totals 1,805 square kilometres, according to its FY2026 results reported on …

Sonal Goyal | 19 October 2026

Why Cullen Resources (ASX:CUL) is watching cash and a Finland partner's exit decision while it follows up Yardilla gold

Cullen describes itself as an Australia-focused minerals explorer, targeting gold and base metals in Western Australia with a priority on greenfields work on wholly owned projects. It also holds joint venture interests, including a 20 per cent stake in the Northern Finland projects, free-carried …

Sonal Goyal | 19 October 2026

Why Cynata Therapeutics (ASX:CYP) Is Reviewing Its Stem Cell Platform After Two Failed Clinical Trials

Cymerus uses induced pluripotent stem cells (iPSCs) to generate mesenchymal stromal cells, which are studied for anti-inflammatory and immune-modulating properties. The aim is a consistent, off-the-shelf cell product from a single cell line rather than donor-derived material.

Sonal Goyal | 19 October 2026
Support

Hi! How can we help you today?

Loading…